{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O43927",
      "entity_text" : "CXCL13",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false,
    "context" : {
      "TissueType" : [ "tissuelist:TS-0068" ],
      "Organ" : [ "uberon:UBERON:0000105" ],
      "CellType" : [ "cl:CL:0000236" ],
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "Clinical response to spebrutinib was associated with a lower increase in total CD19 + B cells in the blood and with a greater decrease in CXCL13 and MIP-1beta levels in the serum.",
  "reading_complete" : "2020-07-28T16:59:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:55:57Z",
  "trigger" : "levels",
  "evidence" : [ "CXCL13 and MIP-1beta levels" ],
  "pmc_id" : "7021855",
  "score" : 0
}